Document is current

Article History

Received: 27 February 2025

Accepted: 22 July 2025

First Online: 31 July 2025

Competing interests

: Rachel Schiff declares research funding/grants to her institution (past and present) from AstraZeneca, GlaxoSmithKline, Puma, Biotechnology Inc, and Gilead Sciences, speaker honoraria and/or travel expenses from Binaytara Foundation and Dava Oncology, LP, and advisory board fees from Eli Lilly Daiichi Sankyo (Ad hoc), and MacroGenics. She declares royalties from UpToDate, is co-inventor in the Baylor College of Medicine’s pending patent application # PCT/US21/70543 (Methods for BC treatment and prediction of therapeutic response), and has served as a member of the SABCS (BC symposium) Faculty/Planning Committees. Laura Biganzoli declares Personal financial interests (Honoraria, consultancy or advisory role): Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Menarini, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, SeaGen. Institutional financial interests: Celgene, Genomic Health, Novartis. Travel grant: AstraZeneca, Daiichi-Sankyo. Luca Malorni declares Honoraria from Pfizer, Novartis, Seagen, Consulting or Advisory Role from Pfizer, Novartis, Seagen, Roche, Menarini Group, Research Funding from Pfizer, Novartis, Travel, Accommodations, Expenses from Roche, Janssen, Gilead Sciences, Menarini Group. All other authors declare no potential conflict of interest.